GlaxoSmithKline plc (LON:GSK) declared a dividend on Wednesday, February 7th, Upcoming.Co.Uk reports. Investors of record on Thursday, February 22nd will be paid a dividend of GBX 23 ($0.32) per share on Thursday, April 12th. This represents a yield of 1.78%. The ex-dividend date of this dividend is Thursday, February 22nd. This is a positive change from GlaxoSmithKline’s previous dividend of $19.00. The official announcement can be accessed at this link.
GlaxoSmithKline (GSK) opened at GBX 1,320.35 ($18.24) on Wednesday. The stock has a market cap of $65,470.00 and a PE ratio of 3,070.58. GlaxoSmithKline has a 12-month low of GBX 1,235.20 ($17.07) and a 12-month high of GBX 1,724.50 ($23.83).
GSK has been the subject of a number of research analyst reports. JPMorgan Chase & Co. set a GBX 1,320 ($18.24) price target on shares of GlaxoSmithKline and gave the company a “neutral” rating in a report on Monday, February 12th. Kepler Capital Markets raised shares of GlaxoSmithKline from a “reduce” rating to a “hold” rating and upped their price target for the company from GBX 1,340 ($18.51) to GBX 1,360 ($18.79) in a report on Friday, February 9th. Barclays reissued an “overweight” rating and issued a GBX 1,650 ($22.80) price target on shares of GlaxoSmithKline in a report on Friday, February 9th. Beaufort Securities raised shares of GlaxoSmithKline to a “buy” rating and upped their price target for the company from GBX 1,450 ($20.03) to GBX 1,500 ($20.72) in a report on Thursday, February 8th. Finally, Berenberg Bank cut their price target on shares of GlaxoSmithKline from GBX 1,760 ($24.32) to GBX 1,705 ($23.56) and set a “buy” rating for the company in a report on Thursday, February 8th. Two research analysts have rated the stock with a sell rating, twelve have given a hold rating and nine have given a buy rating to the company. The company presently has a consensus rating of “Hold” and an average target price of GBX 1,540.45 ($21.28).
In other GlaxoSmithKline news, insider Patrick Vallance sold 14,022 shares of the stock in a transaction that occurred on Monday, February 19th. The stock was sold at an average price of GBX 1,318 ($18.21), for a total transaction of £184,809.96 ($255,332.91). Also, insider Sir Roy Anderson purchased 562 shares of the stock in a transaction on Wednesday, February 7th. The shares were bought at an average price of GBX 1,278 ($17.66) per share, for a total transaction of £7,182.36 ($9,923.13). In the last 90 days, insiders purchased 590 shares of company stock worth $754,966 and sold 43,765 shares worth $57,352,709.
TRADEMARK VIOLATION WARNING: “GlaxoSmithKline plc (GSK) Plans Dividend Increase – GBX 23 Per Share” was published by Stock Observer and is the sole property of of Stock Observer. If you are accessing this article on another website, it was stolen and republished in violation of US and international trademark & copyright legislation. The correct version of this article can be read at https://www.thestockobserver.com/2018/02/21/glaxosmithkline-plc-gsk-plans-dividend-increase-gbx-23-per-share.html.
GlaxoSmithKline Company Profile
GlaxoSmithKline plc is a global healthcare company. The Company operates through three segments: Pharmaceuticals, Vaccines and Consumer Healthcare. The Company focuses on its research across six areas: Respiratory diseases, human immunodeficiency virus (HIV)/infectious diseases, Vaccines, Immuno-inflammation, Oncology and Rare diseases.
Receive News & Ratings for GlaxoSmithKline Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for GlaxoSmithKline and related companies with MarketBeat.com's FREE daily email newsletter.